Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)
The India experience gives you a live case study of what could happen as GLP-1 patents expire in more markets, especially if regulators and payers push harder on costs
Mukherjee, A., Hum, A., Gustafson, T
Homegrown firms are quickly moving via Phase 3 trials to challenge early market leaders, ensuring that Chinese companies will secure a major foothold in one of the world's fastest-growing drug classes
US$ 29.56
US$ 27.19
US$ 24.27
US$ 26.38
